

ASX ANNOUNCEMENT

10 February 2025

Change of Chairperson

10 February 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) advises that Dr. Julian Chick has formally tendered his resignation as Chair of Cann, effective today. Julian's workload in his full-time executive role at ReNerve Limited has expanded considerably and requires frequent international travel, such that he does not have the capacity to dedicate to the role of Chair of Cann at the present time.

Julian has been a valuable member of the Board since he joined in the Board in October 2022, and has provided excellent support to Jenni Pilcher as CEO. The Cann Board wishes Julian all the very best success in his expanded and demanding role.

The Company is currently recruiting for a new Chair and has identified several suitable external candidates. In addition, Julian has agreed to be available for handover to a new Chair over the next three months as required.

Mr Doug Rathbone will be filling the role of interim Chair.

-ENDS-

Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com